Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “cells”

914 pharma patents match "cells" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 914
Index total 30,257
Page 2 / 39

Quick answer

This filtered view shows 914 pharmaceutical patents matching "cells" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

914 results for “cells” · 30,257 patents in full index Clear search

  1. US 12310992

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted May 27, 2025 · Expires May 22, 2045

    granted
  2. US 12310986

    Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress

    The Board of Regents of the University of Texas System · Granted May 27, 2025 · Expires May 22, 2045

    granted
  3. US 12304968

    T-cells expressing anti-LIV1 chimeric antigen receptor

    CRISPR THERAPEUTICS AG · Granted May 20, 2025 · Expires May 15, 2045

    granted
  4. US 12297452

    Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-cells

    The Regents of the University of California · Granted May 13, 2025 · Expires May 8, 2045

    granted
  5. US 12275966

    Genetically engineered cells

    The Regents of the University of California · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  6. US 12274684

    Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

    United Therapeutics Corporation · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  7. US 12268700

    3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  8. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    The Board of Regents of the University of Texas System · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  9. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  10. US 12251403

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  11. US 12241087

    Compositions and methods for differentiating stem cells into NK cells

    CRISPR THERAPEUTICS AG · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  12. US 12234480

    Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells

    Regents of the University of Minnesota · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  13. US 12227554

    Methods for selectively expanding cells expressing a TCR with a murine constant region

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  14. US 12228572

    Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

    The First Hospital of China Medical University · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  15. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  16. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  17. US 12221629

    Methods for producing fibroadipogenic progenitor cells

    Regents of the University of Minnesota · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  18. US 12221622

    Modified pluripotent cells

    The Regents of the University of California · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  19. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Allogene Therapeutics, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  20. US 12221627

    Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  21. US 12215349

    Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  22. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  23. US 12215162

    BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

    The Board of Regents of the University of Texas System · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  24. US 12209255

    Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

    Astellas Institute for Regenerative Medicine · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted